keyword
https://read.qxmd.com/read/38627860/hemophagocytic-lymphohistiocytosis-and-macrophage-activation-syndrome-two-rare-sides-of-the-same-devastating-coin
#21
REVIEW
Flavio Sztajnbok, Adriana Rodrigues Fonseca, Leonardo Rodrigues Campos, Kátia Lino, Marta Cristine Félix Rodrigues, Rodrigo Moulin Silva, Rozana Gasparello de Almeida, Sandro Félix Perazzio, Margarida de Fátima Fernandes Carvalho
Hemophagocytic lymphohistiocytosis (HLH) is a rare genetic hyperinflammatory syndrome that occurs early in life. Macrophage activation syndrome (MAS) usually refers to a secondary form of HLH associated with autoimmunity, although there are other causes of secondary HLH, such as infections and malignancy. In this article, we reviewed the concepts, epidemiology, clinical and laboratory features, diagnosis, differential diagnosis, prognosis, and treatment of HLH and MAS. We also reviewed the presence of MAS in the most common autoimmune diseases that affect children...
April 16, 2024: Advances in Rheumatology
https://read.qxmd.com/read/38627240/prosthetic-infections-following-tocilizumab-treatment-in-patients-with-rheumatoid-arthritis
#22
JOURNAL ARTICLE
A Louters, M Van Oosterhout, L Burgemeister, N T Jessurun, J A Van Lint
No abstract text is available yet for this article.
April 16, 2024: Rheumatology
https://read.qxmd.com/read/38625671/efficacy-and-safety-of-secukinumab-in-us-patients-with-psoriatic-arthritis-a-subgroup-analysis-of-the-phase-3-future-studies
#23
JOURNAL ARTICLE
Alan J Kivitz, Joel M Kremer, Clarence W Legerton, Luminita Pricop, Atul Singhal
INTRODUCTION: The aim of this work is to evaluate secukinumab vs. placebo in a challenging-to-treat and smaller US patient subpopulation of the international FUTURE 2-5 studies in patients with psoriatic arthritis (PsA). METHODS: Data were pooled from US patients enrolled in the phase 3 FUTURE 2-5 studies (NCT01752634, NCT01989468, NCT02294227, and NCT02404350). Patients received secukinumab 300 or 150 mg with subcutaneous loading dose, secukinumab 150 mg without subcutaneous loading dose, or placebo...
April 16, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38625384/patient-reported-outcomes-of-curcumin-supplementation-in-rheumatoid-arthritis-and-psoriatic-arthritis-a-cross-sectional-survey
#24
JOURNAL ARTICLE
Richa Purohit, Neha Bhaskar, Tara Jehu, Kathlyn Camargo Macias, Sweta Chalise, Neha Bhanusali
Curcumin is suggested to possess potent anti-inflammatory properties. This study focuses on determining the prevalence and perceived efficacy of curcumin supplementation in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) population. We conducted a cross-sectional study on patients with RA and PsA who visited a rheumatology outpatient clinic from October 2019 to March 2020. A brief, voluntary, and anonymous Qualtrics survey of specific questions regarding curcumin use, source, form, method, dosage, side effects, and perceived efficacy was distributed to the patients...
April 16, 2024: Rheumatology International
https://read.qxmd.com/read/38623986/hormonal-imbalance-in-obesity-and-arthritis-points-of-contact
#25
JOURNAL ARTICLE
Sukanya Vijayan, Thirumal Margesan
Obesity is a growing global health crisis intricately connected to various chronic conditions, including arthritis. This paper explores the intricate web of hormonal changes in the context of obesity and their profound influence on the development and progression of arthritis. Hormones, such as leptin, insulin, cortisol, and estrogen, all altered in obesity, play pivotal roles in inflammation, cartilage degradation, mechanical stress, and pain associated with obesity-related arthritis. Additionally, the mechanical stress placed on weight-bearing joints by excess body weight accelerates joint wear and tear, contributing to arthritis...
April 15, 2024: Current Rheumatology Reviews
https://read.qxmd.com/read/38622711/prevalence-of-spondyloarthritis-in-inflammatory-bowel-disease-according-asas-and-ultrassonography-and-its-correlation-with-plasma-calprotectin
#26
JOURNAL ARTICLE
Míriam Küster Huber, Valeria Valim, Érica Vieira Serrano, José Alexandre Mendonça, Rafael Burgomeister Lourenço, Thaisa Moraes Ribeiro Espírito Santo, Hilde Nordal, Maria de Fátima Bissoli, Maria Bernadete Renoldi de Oliveira Gavi
BACKGROUND: Enteropathic spondyloarthritis is underdiagnosed and inflammatory biomarkers and ultrasonography (US) could be useful for screening inflammatory bowel disease (IBD) patients. The objective of this study was to evaluate the prevalence of spondyloarthritis (SpA) in IBD patients, according to the Assessment of SpondyloArthritis International Society (ASAS) criteria and the correlation of results of US of entheses and joints with plasma calprotectin levels. METHODS: This was an observational cross-sectional study...
April 15, 2024: Advances in Rheumatology
https://read.qxmd.com/read/38622706/drug-survival-and-change-of-disease-activity-using-a-second-janus-kinase-inhibitor-in-patients-with-difficult-to-treat-rheumatoid-arthritis-who-failed-to-a-janus-kinase-inhibitor-and-subsequent-biologics
#27
JOURNAL ARTICLE
Oh Chan Kwon, Wonho Choi, Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Min-Chan Park, Yong-Gil Kim
BACKGROUND: To assess the drug survival and change of disease activity using a second Janus kinase inhibitor (JAKi) after failure to a JAKi and subsequent biologic disease-modifying anti-rheumatic drugs (bDMARDs) in patients with difficult-to-treat rheumatoid arthritis (RA). METHODS: This retrospective cohort study included 32 patients with difficult-to-treat RA who failed to a JAKi and subsequently to one or more bDMARDs and then switched to a second JAKi. To assess drug survival, electronic medical records of each patient were reviewed...
April 15, 2024: Advances in Rheumatology
https://read.qxmd.com/read/38622428/evaluation-of-inflammatory-biomarkers-and-the-ratio-of-hemoglobin-red-cell-distribution-width-in-patients-with-rheumatoid-arthritis-treated-with-tumor-necrosis-factor-alpha-inhibitors
#28
JOURNAL ARTICLE
Ayşegül Yetişir, Aylin Sariyildiz, İpek Türk, Ilke Coskun Benlidayi
BACKGROUND: The aim of this study was to examine pre-treatment and post-treatment hemogram-derived inflammatory biomarkers in patients with rheumatoid arthritis (RA) who received anti-tumor necrosis factor (TNF)-α treatment. MATERIAL AND METHODS: The data of 1182 patients with RA were screened. Among them, 207 patients who met the eligibility criteria were included in the retrospective study. Demographic parameters, disease activity, and blood cell-derived indexes were evaluated...
April 15, 2024: Clinical Rheumatology
https://read.qxmd.com/read/38622108/the-diagnostic-accuracy-of-raman-spectroscopy-integrated-with-polarized-light-microscopy-for-calcium-pyrophosphate-associated-arthritis
#29
JOURNAL ARTICLE
Tom Niessink, Matthijs Janssen, Tanja Giesen, Monique N Efdé, Antoaneta C Comarniceanu, Cees Otto, Tim L Jansen
BACKGROUND: We studied the performance of integrated Raman Polarized light Microscopy (iRPolM) for the identification of calcium pyrophosphate (CPP) associated arthritis (CPPD) METHODS: This is a diagnostic accuracy study including 400 consecutive synovial fluid samples from a single hospital in the Netherlands. Accuracy measures were calculated against polarized light microscopy (PLM) and the 2023 ACR/EULAR criteria set for CPPD. RESULTS: The interrater reliability between iRPolM and the 2023 ACR/EULAR criteria set for CPPD was strong (k = 0...
April 15, 2024: Arthritis Care & Research
https://read.qxmd.com/read/38622107/american-college-of-rheumatology-acr-and-food-and-drug-administration-fda-summit-summary-of-the-meeting-may-17-18-2022
#30
JOURNAL ARTICLE
Jonathan Kay, Nikolay P Nikolov, Michael H Weisman
On May 17-18, 2022, the ACR and the FDA co-sponsored a public meeting to address topics of mutual interest and importance in assessing long-term safety and clinical efficacy, as well as novel approaches to clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). During the two-day consensus-building summit, rheumatologists, other health care professionals, and FDA staff provided a broad perspective on current clinical development challenges and potential approaches to address them. Key takeaways are summarized in this document, including issues related to innovative clinical trial designs, use of novel outcome measures such as magnetic resonance imaging (MRI) and patient-reported outcomes (PROs), and use of innovative approaches to collecting data including registries and digital health technology (DHT)...
April 15, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38622106/detection-of-interstitial-lung-disease-in-rheumatoid-arthritis-by-thoracic-ultrasound-a-diagnostic-test-accuracy-study
#31
JOURNAL ARTICLE
Bjørk K Sofíudóttir, Stefan Harders, Christian B Laursen, Philip R Lage-Hansen, Sabrina M Nielsen, Søren A Just, Robin Christensen, Jesper R Davidsen, Torkell Ellingsen
OBJECTIVE: The Objective was to determine the diagnostic accuracy of thoracic ultrasound (TUS) for detecting (ILD) in rheumatoid arthritis (RA) with respiratory symptoms. METHODS: Individuals with RA visiting Rheumatological outpatient clinics in the Region of Southern Denmark were systematically screened for dyspnoea, cough, recurrent pneumonia, prior severe pneumonia or a chest X-ray indicating interstitial abnormalities. Eighty participants with a positive screening were consecutively included...
April 15, 2024: Arthritis Care & Research
https://read.qxmd.com/read/38622089/implementing-a-staff-led-smoking-cessation-intervention-in-a-diverse-safety-net-rheumatology-clinic-a-pre-post-scalability-study-in-a-low-resource-setting
#32
JOURNAL ARTICLE
Jennifer Brandt, Edmond Ramly, S Sam Lim, Gaobin Bao, Monica L Messina, Megan E Piper, Christie M Bartels
OBJECTIVES: Quit Connect (QC), our specialty clinic smoking cessation intervention, supports clinic staff to check, advise, and connect willing patients to a state quit line or class. QC improved tobacco screening and quit line referrals 26-fold in a predominantly White academic healthcare system population. Implementing QC includes education, electronic health record (EHR) reminders, and periodic audit feedback. This study tested QC's feasibility and impact in a safety-net rheumatology clinic with a predominantly Black population...
April 15, 2024: Arthritis Care & Research
https://read.qxmd.com/read/38622070/the-unique-interplay-between-antinuclear-antibodies-and-nuclear-molecules-in-the-pathogenesis-of-sle
#33
REVIEW
David S Pisetsky
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that primarily affects young women and causes a wide range of inflammatory manifestations. The hallmark of SLE is the production of antibodies to components of the cell nucleus (antinuclear antibodies or ANAs). These antibodies can bind to DNA, RNA and protein complexes with nucleic acids. Among ANAs, antibodies to DNA (anti-DNA) are markers for classification and disease activity, waxing and waning in many patients. In the blood, anti-DNA antibodies can bind DNA to form immune complexes with two distinct roles in pathogenesis: renal deposition to provoke nephritis and stimulation of cytokine production following uptake into innate immune cells and interaction with internal nucleic acid sensors...
April 15, 2024: Arthritis & Rheumatology
https://read.qxmd.com/read/38621798/feasibility-of-physiotherapist-led-rheumatology-triage-a-randomized-study
#34
JOURNAL ARTICLE
Janet H Roberts, Cheri Gun, Jennifer E Mackinnon, Susan Parlee, Volodko Bakowsky, Trudy Taylor, Claire E H Barber, John G Hanly
OBJECTIVE: Given global shortages in the rheumatology workforce, the demand for rheumatology assessment often exceeds the capacity to provide timely access to care. Accurate triage of patient referrals is important to ensure appropriate utilization of finite resources. We assessed the feasibility of physiotherapist-led triage utilizing a standardized protocol, in identifying cases of inflammatory arthritis (IA), as compared to usual rheumatologist triage of referrals for joint pain, in a tertiary care rheumatology clinic...
April 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38621797/when-should-i-get-my-next-covid-vaccine-data-from-the-surveillance-of-responses-to-covid-19-vaccines-in-systemic-immune-mediated-inflammatory-diseases-succeed-study
#35
JOURNAL ARTICLE
Dawn M E Bowdish, Vinod Chandran, Carol A Hitchon, Gilaad G Kaplan, J Antonio Avina-Zubieta, Paul R Fortin, Maggie J Larché, Gilles Boire, Anne-Claude Gingras, Roya M Dayam, Ines Colmegna, Luck Lukusa, Jennifer L F Lee, Dawn P Richards, Daniel Pereira, Tania H Watts, Mark S Silverberg, Charles N Bernstein, Diane Lacaille, Jenna Benoit, John Kim, Nadine Lalonde, Janet Gunderson, Hugues Allard-Chamard, Sophie Roux, Joshua Quan, Lindsay Hracs, Elizabeth Turnbull, Valeria Valerio, Sasha Bernatsky
OBJECTIVE: To determine how serologic responses to COVID vaccination/infection in immunemediated inflammatory disease (IMID) are affected by time since last vaccination and other factors. METHODS: Post-COVID-19 vaccination, data and dried blood spots/sera were collected from adults with rheumatoid arthritis, inflammatory bowel disease, systemic lupus, ankylosing spondylitis/spondylarthritis and psoriasis/psoriatic arthritis. First sample was at enrolment and then 2-4 weeks and 3, 6, and 12 months after latest vaccine dose...
April 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38621796/knowledge-of-and-stated-adherence-to-the-2020-acr-guideline-for-gout-management-results-of-a-survey-of-us-rheumatologists
#36
JOURNAL ARTICLE
Naomi Schlesinger, Michael H Pillinger, Peter E Lipsky
OBJECTIVE: This report evaluates rheumatologists' stated adherence to and agreement with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout. METHODS: A 57-item questionnaire was administered to US rheumatologists. Stated adherence scores were based on several guideline recommendations reported to be followed by rheumatologists in practice, whereas stated agreement scores were based on whether respondents always followed the recommendations...
April 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38621795/fibromyalgia-and-the-difficult-synthesis
#37
EDITORIAL
Marco Di Carlo, Benedetta Bianchi, Fausto Salaffi
The pathophysiological uncertainties in fibromyalgia (FM) mean that its diagnosis, to this day, remains a strictly clinical exercise. The physician's evaluation of symptoms is therefore of fundamental importance both for the correct diagnostic framing of the patient and also for guiding a personalized therapeutic approach.1 .
April 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38621794/patient-initiated-follow-up
#38
JOURNAL ARTICLE
Edward Alveyn, James Galloway, Laura C Coates
In the contemporary healthcare climate, we are acutely aware that our resources are finite. This is particularly pertinent in government-funded healthcare settings, where clinical teams often face the challenge of meeting increasing patient demand with static or dwindling capacity.1-4 .
April 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38621793/upadacitinib-in-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-disease-modifying-antirheumatic-drugs-efficacy-and-safety-through-5-years-select-next
#39
JOURNAL ARTICLE
Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz
OBJECTIVE: To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT. METHODS: Patients on stable conventional synthetic disease-modifying antirheumatic drugs were randomized to upadacitinib 15 mg, upadacitinib 30 mg once daily (UPA15/30), or placebo for 12 weeks. Following this, placebo-randomized patients were switched to UPA15 or UPA30 in the LTE; upadacitinib-randomized patients continued their original dose...
April 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38621792/asdas-crp-and-asdas-esr-cut-offs-for-disease-activity-states-in-axial-spondyloarthritis-are-they-interchangeable
#40
JOURNAL ARTICLE
Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Brigitte Michelsen, Tore K Kvien, Daniela Di Giuseppe, Johan K Wallman, Jakub Závada, Sella A Provan, Eirik Klami Kristianslund, Ana Maria Rodrigues, Maria José Santos, Žiga Rotar, Katja Perdan Pirkmajer, Dan Nordström, Gary J Macfarlane, Gareth T Jones, Irene van der Horst-Bruinsma, Pasoon Hellamand, Mikkel Østergaard, Merete Lund Hetland
OBJECTIVE: Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs (1.3, 2.1 and 3.5) and investigate the potential improvement of level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states when applying these estimated cut-offs...
April 15, 2024: Journal of Rheumatology
keyword
keyword
89631
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.